BioSpace News Archive

Admiral Kirkland “Kirk” Donald, U.S. Navy and member of Battelle’s Board of Directors since 2015, was elected Chairman of the Battelle Board, effective immediately.

iQure Pharma Inc. (iQure), a US-based global biotech company, has confirmed through preclinical screenings that iQ-007, a novel anticonvulsant and analgesic compound, showed no binding to targets in the drug abuse potential panel.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or the “Company”) is pleased to announce that it has closed the second tranche (the “Second Tranche”) of its non-brokered private placement of convertible notes (the “Notes”) previously announced on October 7, 2022.

Lyndra Therapeutics today announced that its LYNX™ drug delivery platform was named the winner of the Fierce Life Sciences Innovation Awards 2022 award in the Drug Delivery Technology category.

The U.S. Department of Health and Human Services and the Cohen Foundation have selected Serimmune as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (LymeX) prize competition to accelerate the development of Lyme disease diagnostics.

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver multiple presentations at the 2022 VEITH Symposium, which is being held November 15 – 19 in New York City.

Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating VG201, a first-in-class HSV Type I oncolytic virus product constructed based on a transcriptional and translational dual-regulated (TTDR) backbone developed by Virogin Biotech.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) (“Ginkgo”),which is building the leading platform for cell programing and biosecurity, today announced that it intends to offer and sell $100 million of its Class A common stock in an underwritten public offering.

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer.

CraniUS LLC, an R&D company focused on building groundbreaking diagnostics and treatments for patients with chronic brain disease, announced today the appointment of Henry Brem, MD to its accomplished Board of Directors.